Regulus Therapeutics' (RGLS) Abstract on RG-101 Not Presented at AASLD Conference

November 14, 2016 4:46 PM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Regulus Therapeutics (NASDAQ: RGLS) said to withdraw abstract n RG-101, which was slated for presentation at AASLD last Saturday, according to Bloomberg.

Regulus' IND for RG-101 was placed on clinical hold in June.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment